192 related articles for article (PubMed ID: 37022638)
1. The Dynamics of Dopamine D
Liu K; Song M; Gao S; Yao L; Zhang L; Feng J; Wang L; Gao R; Wang Y
Neurosci Bull; 2023 Sep; 39(9):1411-1425. PubMed ID: 37022638
[TBL] [Abstract][Full Text] [Related]
2. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
3. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
4. Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
Bagetta V; Sgobio C; Pendolino V; Del Papa G; Tozzi A; Ghiglieri V; Giampà C; Zianni E; Gardoni F; Calabresi P; Picconi B
J Neurosci; 2012 Dec; 32(49):17921-31. PubMed ID: 23223310
[TBL] [Abstract][Full Text] [Related]
5. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
[TBL] [Abstract][Full Text] [Related]
6. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
7. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
[TBL] [Abstract][Full Text] [Related]
8. Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats.
Kiessling CY; Lanza K; Feinberg E; Bishop C
Neuropharmacology; 2020 Sep; 174():108138. PubMed ID: 32492451
[TBL] [Abstract][Full Text] [Related]
9. BDNF/TrkB pathway activation in D1 receptor-expressing striatal projection neurons plays a protective role against L-DOPA-induced dyskinesia.
Pelosi A; Nakamura Y; Girault JA; Hervé D
Neurobiol Dis; 2023 Sep; 185():106238. PubMed ID: 37495178
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
11. Striatal D
Gao S; Gao R; Yao L; Feng J; Liu W; Zhou Y; Zhang Q; Wang Y; Liu J
Front Aging Neurosci; 2022; 14():783893. PubMed ID: 35185524
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
13. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of striatal dopamine D
Wang Y; Yao L; Gao S; Zhang G; Zhang Q; Liu W; Zhou Y; Sun Y; Feng J; Liu J
Brain Res; 2021 Mar; 1754():147266. PubMed ID: 33422541
[TBL] [Abstract][Full Text] [Related]
15. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
Morin N; Morissette M; Grégoire L; Di Paolo T
Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
[TBL] [Abstract][Full Text] [Related]
16. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Smith LM; Parr-Brownlie LC; Duncan EJ; Black MA; Gemmell NJ; Dearden PK; Reynolds JN
Neuroscience; 2016 Jun; 324():238-51. PubMed ID: 26968766
[TBL] [Abstract][Full Text] [Related]
17. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
Lindenbach D; Ostock CY; Eskow Jaunarajs KL; Dupre KB; Barnum CJ; Bhide N; Bishop C
J Pharmacol Exp Ther; 2011 Jun; 337(3):755-65. PubMed ID: 21402691
[TBL] [Abstract][Full Text] [Related]
18. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
19. Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Wang Y; Zhang GJ; Sun YN; Yao L; Wang HS; Du CX; Zhang L; Liu J
Behav Brain Res; 2018 Jul; 347():175-183. PubMed ID: 29551735
[TBL] [Abstract][Full Text] [Related]
20. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Wang Y; Wang HS; Wang T; Huang C; Liu J
J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
